Bristol Myers Squibb said its pivotal GPRC5D-directed CAR-T trial in multiple myeloma hit its primary endpoint, advancing a key program aimed at challenging the post-BCMA landscape. The company positioned the result as a step toward a broader commercial opportunity as competitors jockey for next-generation target space. The Phase 2 readout adds to ongoing efforts in CAR-T design that attempt to extend durability or deepen responses in patients whose disease progresses after existing cell-therapy approaches. For the industry, a positive endpoint at the pivotal stage typically accelerates planning for later-line studies and potential label expansions. The multiple myeloma market remains one of the most intensively contested arenas in hematologic oncology, and GPRC5D has been viewed as a strategic alternative to BCMA-dependent options.